BioSpace News Archive

Medigene AG provides a detailed overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell therapy, at the 7th Cell and Gene Therapy In-Depth Focus Summit from June 27-28, 2024, in Beijing, China.

X4 Pharmaceuticals announced positive new clinical data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of mavorixafor, an oral CXCR4 antagonist, in the treatment of people with chronic neutropenia.

Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.

Natera, Inc., a global leader in cell-free DNA and genetic testing, announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company’s personalized and tumor-informed molecular residual disease test, Signatera™, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer.

Zomedica Corp. announced the commercial launch of its second equine focused assay - Cortisol for equine serum - for the point-of-care TRUFORMA® diagnostic platform.

Oncolytics Biotech® Inc. announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration, supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer.

OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests and sample management solutions announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Testing Day, held each year on June 27th.

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced plans to host a virtual key opinion leader event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced progress updates for its two lead programs, MRT-2359, an MGD being developed for MYC-driven solid tumors, and MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases.